日期: 2026 年 3 月 27 日

SYDNEY, AU, Mar 28, 2026 - (ACN Newswire via SeaPRwire.com) - Vantage Goldfields Limited (Vantage Goldfields) owns Vantage Goldfields Pty Ltd (VGL), Barbrook Mines Pty Ltd (Barbrook) and Makonjwaan Imperial Mining Company (Pty) Ltd (MIMCO) (collectively the Vantage Companies), which own the Lily and Barbrook mines in South Africa. The Vantage Companies are currently in business rescue in South Africa, which is the legal process that assists financially distressed companies restructure, or otherwise avoid liquidation.An announcement was made on 26 March 2026 by TSX-V listed Lions Bay Capital Inc. (Lions Bay), which the Vantage Companies believe is misleading to investors and fails to disclose material information (the Announcement). That Announcement referred to Lions Bay receiving approval from a business rescue practitioner (BRP) of the Vantage Companies and calling a meeting of creditors to approve business rescue plans for the Vantage Companies.The Announcement is misleading and fails to disclose relevant material information regarding the Vantage Companies and Lions Bay proposal, including:While the Announcement referred to a Business Rescue Practitioner (BRP) (being Mr Devereux) approving the Lions Bay proposal, it failed to disclose that the Vantage Companies have two appointed BRPs and the second BRP has not approved the Lions Bay's proposal. Both BRPs have to approve a proposal in order for it to be presented to creditors. The second BRP was appointed by the Boards of the Vantage Companies, and his appointment was confirmed by the Companies and Intellectual Property Commission (CIPC), the corporate regulator in South Africa.The second BRP was appointed to ensure that all viable proposals for the rescue of the Vantage Companies are properly considered and that a business rescue is then properly and lawfully implemented for the benefit of all stakeholders, including creditors, former employees and the local community, as soon as possible.Vantage Goldfields as the owner of the Vantage Companies and Lily and Barbrook mines, has received a number of viable proposals for the rescue of the Vantage Companies and the reopening of those mines, which should be properly considered by the BRPs. These proposals should result in a better outcome for creditors and other stakeholders of the Vantage Companies than the Lions Bay proposal.Mr. Devereux acted unilaterally and unlawfully in purporting to approve an offer from Lions Bay and convene a meeting of creditors of the Vantage Companies. Vantage Goldfields believes that Mr. Devereux misled such creditors by failing to disclose that Lions Bay does not have the necessary US$40 million in funds to be able to complete its proposal.The Announcement failed to disclose that for the Lions Bay proposal to be able to be implemented, an approval from a BRP is not legally sufficient to be able to implement that proposal, and that proposal would need to be approved by specified majorities of creditors of each of the Vantage Companies. Vantage Goldfields has been informed by the largest secured creditor of the Vantage Companies that it does not support and will not vote in favour of the Lions Bay proposal at the necessary meetings of creditors, on its current terms and given that Lions Bay does not have all the necessary funds to complete the proposal. That creditor also has not agreed to release its securities over the asset of the Vantage Companies.Therefore, the necessary approvals of creditors will not be obtained, and the Lions Bay proposal will not be able to be implemented as currently proposed.Vantage Goldfields intends to ensure that all viable proposals are properly considered for the business rescue of the Vantage Companies, and that the business rescue process is progressed and implemented properly in accordance with South African law. Vantage Goldfields remains fully committed to reopening the Lily and Barbrook mines for the benefit of all creditors, former employees, affected persons and other stakeholders of the Vantage Companies.Stephen TurnerChairman-Vantage Goldfieldsst@stephenturner.com.auThis press release contains forward-looking statements, including statements about our future operations, plans, objectives, expectations, estimates, forecasts, or projections. Forward-looking statements are inherently subject to known and unknown risks, uncertainties, assumptions, and other factors that may cause actual results, performance, or outcomes to differ materially from those expressed or implied.Under Australian law, statements about future matters must be based on reasonable grounds at the time they are made or they may be considered misleading. We believe the forward-looking statements in this release are based on reasonable grounds; however, events or circumstances may cause actual results to differ.These risks and uncertainties may include, among other things, changes in market conditions, economic factors, industry developments, operational challenges, regulatory changes, and other factors known or unknown to the company.Forward-looking statements speak only as of the date of this release, and except as required by law, the company undertakes no obligation to update or revise any forward-looking statements to reflect new information, future events, or changed circumstances.Source: Vantage Goldfields Limited Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 27, 2026 - (ACN Newswire via SeaPRwire.com) - In the Hong Kong stock market, the key to consistently winning investor trust lies not just in periodic earnings growth, but in the ability to stably transform operating results into shareholder returns. According to the latest 2025 annual results report disclosed by Shoucheng Holdings (0697.HK), the company proposes a dividend of 780 million HKD, corresponding to an average annual market value dividend yield of approximately 5.6%. Looking at the long term, since its strategic transformation in 2018, the company has continuously advanced business transformation and structural optimization, leading to steady improvements in profitability and cash flow quality. It has maintained stable dividends for many consecutive years, with a cumulative dividend scale of approximately 6 billion HKD over eight years, shifting the investment logic from "growth expectations" toward "balancing both growth and returns".It is noteworthy that this dividend does not rely on high leverage or short-term overdrafts; rather, it is a proactive return built on improved balance sheets, enhanced operating quality, and optimized cash flow. As of December 31, 2025, the company's bank balances and cash stood at 3.671 billion HKD, with total borrowings of 979 million HKD. The cash-to-interest-bearing debt coverage ratio is approximately 3.75 times, demonstrating strong dividend sustainability and a significant financial safety margin.Over the past eight years, Shoucheng Holdings has gradually formed a smart infrastructure asset service system centered on parking asset management, industrial space management, REITs investment, and equity investment, constructing a composite model of "operational efficiency + asset management + capital circulation". Mature businesses such as parking and industrial parks continue to provide steady cash flow, serving as the practical foundation for the company's dividends. Meanwhile, REITs investments, the robotics ecosystem, and emerging industry funds further open up space for profit realization and valuation enhancement.Among these, the robotics business is becoming a significant incremental driver of Shoucheng Holdings' long-term value. In recent years, the company has continuously refined its robotics layout around "investment + operations + ecosystem," systematically investing in several leading robotics enterprises. Through scenario integration, channel construction, and industrial services, it has pushed projects from technical verification to commercial implementation. As relevant companies accelerate financing, see valuation increases, or move toward IPOs, the robotics segment is expected to continuously strengthen the company's mid-to-long-term profit release and shareholder return capabilities.Furthermore, in the latest Chairman's Statement, Chairman Zhao Tianyang explicitly expressed "gratitude" to investors and continued to emphasize "creating long-term value for investors". This statement is not merely a declaration of attitude but sends a clear signal: Shoucheng Holdings is placing shareholder returns and long-termism in a more prominent position. For the market, the significance of eight years of continuous dividends has long transcended a simple profit distribution; it serves as a more certain anchor of confidence for long-term capital amidst complex economic cycles. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月27日 - (亞太商訊 via SeaPRwire.com) - 在港股市場中，真正能夠持續贏得投資人信任的，不只是階段性的業績增長，更是將經營成果穩定轉化為股東回報的能力 。根據首程控股(0697.HK)最新披露的2025年全年業績報告，公司擬分紅7.8億港元，對應年度平均市值派息率約5.6% 。若將時間拉長，自2018年戰略轉型以來，公司持續推進業務轉型與結構優化，盈利能力與現金流質量不斷提升，已連續多年保持穩定分紅，八年累計分紅規模約60億港元，投資邏輯正從「成長預期」進一步走向「成長與回報並重」 。值得關注的是，這一分紅並非依賴高槓桿或短期透支，而是建立在資產負債表改善、經營質量提升和現金流優化基礎上的主動回報 。截至2025年12月31日，公司銀行結餘及現金為36.71億港元，借款總額為9.79億港元，現金對有息負債覆蓋倍數約為3.75倍，顯示出較強的分紅可持續性和財務安全邊際 。過去八年，首程控股逐步形成以停車資產管理、產業空間管理、REITs投資與股權投資為核心的智能基礎設施資產服務體系，構建起「運營提效+資產管理+資本循環」的複合模式 。停車、園區等成熟業務持續提供穩健現金流，成為公司分紅的現實底盤；REITs投資、機器人生態及新興產業基金，則進一步打開了收益兌現與估值提升空間 。其中，機器人業務正成為首程控股未來長期價值的重要增量 。近年來，公司圍繞「投資+運營+生態」持續完善機器人佈局，系統投資多家頭部機器人企業，並通過場景導入、渠道建設和產業服務，推動項目由技術驗證走向商業落地 。隨著相關企業融資提速、估值提升乃至邁向IPO，機器人板塊有望持續增強公司中長期利潤釋放與股東回報能力 。更值得一提的是，在最新主席報告書中，主席趙天旸明確表達了對投資人的「感恩」，並繼續強調「為投資人創造長期價值」 。這一表述並非簡單態度宣示，更釋放出清晰信號：首程控股正把股東回報與長期主義放在更加重要的位置 。對市場而言，八年持續分紅的意義，也早已超越一次利潤分配本身，而是在複雜週期中，為長期資本提供更具確定性的信心錨點 。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, March 23, 2026 - (ACN Newswire via SeaPRwire.com) - Everest Medicines today announced that it has entered into an Asset Purchase Agreement with Corxel Pharmaceuticals Hong Kong Limited ("CORXEL"). Under the agreement, the Company has acquired the rights to develop, manufacture, and commercialize CARDAMYST™ (etripamil) nasal spray in Greater China, including Chinese Mainland, Hong Kong, Macao and Taiwan region.Under the terms of the agreement, Everest will pay CORXEL an upfront payment of US$30 million (equivalent to approximately RMB344,895,000), as well as potential development milestone payments of up to US$20 million (equivalent to approximately RMB137,958,000). As part of this agreement, Everest will be assigned and transferred rights, interests, claims, duties, obligations and liabilities (other than certain excluded liabilities) under the Milestone License Agreement entered into by CORXEL in May 2021 and certain related ancillary agreements.CARDAMYST™ (etripamil) nasal spray is a novel, rapid-acting calcium channel blocker as administered as needed via a convenient, portable nasal spray. It offers rapid onset of action, favorable tolerability, and the potential for at-home self-administration, enhancing patient accessibility. In December 2025, CARDAMYST was approved by the U.S. Food and Drug Administration (FDA), becoming the first and only self-administered nasal spray in more than 30 years capable of converting paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. As a rapid-acting treatment option, CARDAMYST can be self-administered outside the emergency department or other healthcare settings, enabling patients to actively manage episodes and gain greater control over their condition. In addition to its approved indication for PSVT, etripamil nasal spray is also under clinical development for atrial fibrillation with rapid ventricular response (AFib-RVR). Phase II trials have shown encouraging results, and Phase III trials are planned, with the potential to further extend its therapeutic impact to a broader patient population.In China, the New Drug Application (NDA) for etripamil nasal spray was accepted by the National Medical Products Administration (NMPA) on January 17, 2025 and is expected to receive approval in the third quarter of 2026.PSVT is characterized by abnormalities in the heart's electrical system that cause sudden unexpected and often severely symptomatic episodes of rapid heart rate. There are currently no approved self-administered, fast-acting, non-injectable therapies for acute PSVT, leaving patients with limited treatment options beyond emergency care. Approximately 2.3 to 4 per 1,000 individuals are affected by PSVT, representing an estimated 3 to 6 million patients in China.AFib-RVR is a type of irregular heart rhythm, characterized by an irregular and elevated heart rate. Its onset is typically gradual, episodes are less likely to terminate spontaneously, and the condition tends to recur, significantly increasing the risk of thromboembolism and serious complications such as stroke and heart failure. In China, atrial fibrillation affects an estimated 1.6% of the population, representing nearly 20 million patients, and is expected to increase with an aging population. Both PSVT and AFib-RVR are associated with a loss of control and a significant psychological burden for patients.Overall, the combined patient population for PSVT and AFib-RVR exceeds 25 million, representing a significantly unmet clinical need that urgently requires more convenient and more effective treatment options.In terms of clinical data, the NDA for etripamil nasal spray was accepted by the NMPA based on data from the pivotal global Phase 3 RAPID study and the China Phase 3 JX02002 study. Both trials met their primary endpoints. Overall, the treatment emergent adverse events (TEAEs) were comparable between the etripamil and placebo groups. The FDA approval of CARDAMYST was supported by a robust clinical program that included safety data from more than 1,800 participants across more than 2,000 PSVT episodes. This included the Phase 3 RAPID trial, a global, randomized, double-blind comparison of etripamil versus placebo, published in The Lancet in 2023. The RAPID trial achieved its primary endpoint, with 64% of participants who self-administered etripamil (N=99) converting from supraventricular tachycardia (SVT) to sinus rhythm within 30 minutes compared with 31% on placebo (N=85) (HR = 2.62; p<0.001). The median time to conversion was 17 minutes (95% CI: 13.4, 26.5) for etripamil versus 54 minutes (95% CI: 38.7, 87.3) for placebo. Etripamil nasal spray is also under clinical development for AFib-RVR. In the randomized, controlled Phase-2 ReVeRA study, etripamil demonstrated rapid and significant reduction in ventricular rate in patients with AFib-RVR, achieving its primary endpoint. A greater number of patients receiving etripamil achieved a ventricular rate of less than 100 bpm (58.3%) than those receiving placebo (4%). The safety profile was consistent with previous studies.From a strategic perspective, this transaction is also seen as an important step for the Company in implementing 2030 Strategy. Driven by its 2030 Strategy, and led by Mr. Yifang Wu, Chairman of the Board, Everest is accelerating growth through a dual-engine approach that combines strategic business development partnerships with in-house R&D. This transaction further strengthens Everest's expanding cardiovascular franchise, building on recent strategic initiatives and reinforcing the Company's disciplined approach to constructing focused therapeutic verticals with meaningful lifecycle expansion potential. Through continued advancement of its pipeline and product portfolio globally, Everest aims to deliver innovative therapies to more patients, create sustainable long-term value, and advance its position to become a leading global biopharmaceutical company."We are pleased to collaborate with CORXEL, this agreement marks an important step in our continued expansion in the cardiovascular field and a meaningful milestone in advancing our growth 2030 strategy," said Mr. Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. "CARDAMYST is currently the only therapy designed for at-home self-administration to enable the acute termination of PSVT and AFib-RVR episodes, addressing a significant unmet medical need among patients in China. We will leverage our clinical development expertise and established commercialization platform to accelerate its advancement and future launch in Greater China, while further strengthening our cardiovascular franchise and unlocking its broader potential across atrial arrhythmias."As the registration and commercialization of Etripamil nasal spray progress, the company aims to further expand its cardiovascular portfolio. Leveraging its established clinical development and commercialization capabilities, Everest Medicines will accelerate the delivery of innovative assets, advance its 2030 strategy, and bring more treatment options to patients. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 27, 2026 - (ACN Newswire via SeaPRwire.com) - As AI accelerates into the inference era, enterprise-grade AI is achieving large-scale deployment, driving an exponential surge in Token consumption and ushering data demand into a new development stage. Against this backdrop, high-quality, structured and scenario-specific professional data has become critical for enterprises to forge core strategic competitiveness in the era of AI.As a leading provider of AI real-time data infrastructure and analysis services in China, Xunce Technology is rapidly solidifying its core position in AI data, driven by industry tailwinds, full-chain technological capabilities and diversified growth engines. Amid the unfolding landscape of the intelligent economy, this ten-year industry stalwart is entering a pivotal window for structural revaluation.Token Value Restructuring: Making Every Data Access Quantifiable and MonetizableFounded in 2016, Xunce Technology has built a full-chain technological system spanning data acquisition, cleansing, standardization, real-time computing and large- model optimization over a decade of development. With AI Data Agent at its core, the Company specializes in millisecond-level real-time data processing, serving a diversified portfolio of industries including finance, urban governance, high-end manufacturing, healthcare, robotics, satellite applications, low-altitude economy, electric power, power grids and energy.As the era of AI inference unfolds, Token is evolving from mere “fuel” to a form of “hard currency”. Maximizing the value of each individual Token has emerged as a central challenge in the large-model inference era. Today, general-purpose large models typically rely on a “computing power for precision” approach, where every inference run generates substantial wasteful Token consumption. Should inference fail, all Tokens expended in the process are lost entirely, which is a common pain-point plaguing general AI systems.By contrast, vertical AI solutions equip general large language models with an external industry “brain” powered by domain-specific data. At its core, such solutions optimize inference logic via business-aware models, enabling upfront task feasibility validation and eliminating Token waste at the source. With deep expertise in professional vertical domain data modeling, Xunce Technology leverages its extensive portfolio of high-quality, scenario-specific proprietary data to act as an “efficiency multiplier” for every Token invocation. This structure translates Token consumption into higher-precision outputs while securing maximal result certainty. Crucially, the Company is developing full-chain capabilities spanning data metering, pricing and settlement, enabling quantifiable and monetizable measurement for every data access. By elevating per-unit Token efficiency, it delivers enhanced business value to enterprise clients.Aligned with this strategy, Xunce’s platform features a “LEGO-inspired” modular architecture, enabling clients to flexibly compose modules tailored to their specific needs. This “assemble-on-demand, adapt-in-real-time” design fosters deep and long-term customer stickiness. The Company also employs a highly flexible pricing framework, with fees structured around module count, processing throughput and other key metrics. Supported by subscription, transaction-based and Token-based payment models, its pricing mechanism precisely aligns with diverse client demands.Currently, Xunce Technology is fully building a full-chain data measurement and settlement system. It is exploring pricing mechanisms tied to large model inference frequency and module usage count, allowing customers to pay for effective Tokens rather than raw computing power consumption.Inflection Point Reached, Profitability ConfirmedDriven by Token value restructuring and innovative business models, Xunce Technology has delivered robust performance and reached a historic inflection point. In H2 2025, the Company posted an adjusted net profit of RMB 50 million, achieving its first positive profitability. Meanwhile, revenue rose from RMB 197.85 million in H1 2025 to RMB 1,086.81 million in H2, representing a 449.32% quarter-on-quarter surge. Amid rapid business expansion, the Company has witnessed a substantial improvement in profitability.Explosive Revenue GrowthReturn to Profit in H2Doubled ARPU & Per Capita GrowthImproved Cash Flow & Operating Metrics+103% Y/YNarrowed by 33%+105% Y/YSignificant Improvement2025 full-year revenue YoY growth2025 full-year adjusted net loss2025 ARPU YoY growth2025 net operating cash flow+449% H/HRMB 50 million+135% Y/YAmple cash on hand in 20252025 H2 revenue HoH growth2025 H2 adjusted net profit2025 per capita revenue YoY growthAverage collection period decreased in 2025For the full year, the Company posted total operating revenue of RMB 1,284.66 million, representing a substantial year-on-year increase of 103.28% and successfully breaking the key milestone of RMB 1 billion in revenue. This signifies that the Company has evolved from an early-stage, technology-driven startup into a new era of platform-based development with scalable and replicable business models.Furthermore, the Company’s combined gross proceeds for 2025 amounted to approximately RMB 792.08 million, representing a substantial increase of 63.44% compared to approximately RMB  484.63 million in the previous year. In terms of adjusted net loss, after deducting one-off non-recurring gains and losses, the Company’s adjusted net loss for 2025 was RMB 54.84 million, representing a significant narrowing of 33% from RMB 82.37 million in 2024.Notably, the Company achieved combined gross margin of 62% in 2025, exceeding that of Cambricon (55%), a leading AI chip provider, and far outpacing general large- model developer Minimax (25.4%). This underscores its high-value strategic positioning and resilient business model in the AI data infrastructure sector.In terms of R&D investment, Xunce Technology has also maintained efficient growth conversion. In 2025, the Company’s R&D expenditure reached RMB 450.44 million, with R&D expenses accounting for 48% of revenue, driving a 105% year-on-year increase in operating revenue. For comparison, Minimax’s R&D expenditure accounted for as high as 219% of its revenue, with a revenue growth rate of 159%. Xunce achieved a comparable expansion pace with a lower R&D intensity.As revenue scale continues to expand and gross margin in new industries gradually stabilize, the Company’s short-term objective is to achieve an inflection point in adjusted net profit. Looking ahead, as the industries already deployed enter a period of margin stabilization and Token-based payment and revenue-sharing models gain accelerated traction, its net profit is poised to improve at an accelerated rate.Driven by Diversified Growth Engines, Business Structure Continuously OptimizedThe robust revenue growth is not accidental, but underpinned by Xunce Technology’s multi-dimensional, systematically structured growth framework.Accelerate cross-industry replication. The Company currently covers 9 major industries, benchmarking Palantir’s 17 industries and leaving ample room for horizontal expansion. Xunce Technology is rapidly deepening its presence in key national strategic sectors such as asset management, telecommunications, electric power, urban management, high-end manufacturing, healthcare, energy, robotics training platforms and commercial aerospace. For each new industry, the Company first completes industry-specific data accumulation over 3 to 5 years, enabling rapid replication and scaled deployment across peer customers thereafter.The business model fosters deep customer value enhancement. As customers evolve from single-module adoption to multi-module deployment, and from pilot trials to full integration into core business workflows, substantial upside potential in ARPU remains. By synergistically lifting Token invocation volume, module usage count and per-Token value, the Company will unlock a new dimension of growth.Steadily expand overseas business and establish a global layout. The Company targets raising its overseas revenue share to 10% to 15% in 2026, and will further escalate its globalization strategy during 2027 and 2028, unlocking new avenues for sustained long-term growth.Cultivate a strategic cooperative ecosystem to forge deep integration with upstream and downstream partners in computing power and algorithms. Xunce Technology is engaging in in-depth collaboration with leading domestic GPU providers and large language model enterprises to build a one-stop solution encompassing “infrastructure computing power, upper-layer applications and data governance,” further solidifying its core position in the AI data infrastructure sector.      Pioneer cutting-edge applications to seize commanding heights in future industries. From robotics data platforms to commercial aerospace, low-altitude economy and power grid systems, Xunce Technology has taken the lead in extending AI infrastructure to emerging sectors with stringent demands for real-time performance and operational reliability. Such mission-critical scenarios with ultra-high requirements for data timeliness and stability serve as a rigorous validation of the Company’s technological advantages. The Company will continue to ramp up R&D investment in frontier fields, refine its technical capabilities through high-end application scenarios and unlock new high-growth, high-value growth tracks for long-term development.Evolving from Data Services to Core AI Economy Infrastructure: Building Sustainable Competitive BarriersFrom a macro perspective, the artificial intelligence data sector is witnessing a profound convergence of five defining trends: a surge in demand for real-time, secure, high-quality data in the era of AI Agent; the rise of domain-specific models elevating professional data as a critical enabler for industry-wide intelligent upgrading; standardization of data interfaces driven by next-generation AI operating systems including Open Claw, positioning Xunce Technology as a core data Token provider; Token-based payment emerging as a new paradigm for the data element market; and the implementation of data asset capitalization policies, spurring a sharp rise in enterprises’ mandatory investment in data governance.At the intersection of these five pivotal trends, Xunce Technology has established a robust fundamental logic for sustained long-term growth. The Company has evolved beyond a traditional data infrastructure provider to become a critical “connector” and “enabler” linking large models, computing power and cloud vendors. By integrating upstream models, downstream computing power and horizontal collaboration with cloud vendors, the Company delivers irreplaceable data-centric value to its enterprise clients.The Company stresses that it shares a natural upstream-downstream synergy with general large-model providers, rather than a competitive dynamic. Analogous to the deep collaboration between GPU manufacturers and model developers, the value of Xunce Technology lies in a mutually reinforcing cycle: the wider the adoption of models by its clients, the greater the opportunity for the Company to deliver services and generate incremental value for clients.Notably, in contrast to niche market players offering only isolated modules such as data cleansing or computing engines, Xunce Technology’s core differentiation lies in its full-process coverage and outcome-driven accountability. The Company provides an end-to-end solution spanning data acquisition, cleansing, standardization, modeling, real-time computing and model tuning, ensuring that final data delivered to clients is clean, accurate, real-time and accessible for model invocation at millisecond latency. Furthermore, through deep integration into clients’ private clouds or on-premises environments, the Company acts as a dedicated data steward, fostering exceptional customer stickiness and forging robust, sustainable competitive barriers.Currently, the Company’s product portfolio and solutions feature more than 300 functional modules, covering a full spectrum of scenarios from data infrastructure to upper-layer analytics applications. In 2025, its active paid clients base reached 230, with an outstanding customer retention rate of 90%. ARPU increased substantially from RMB 2.72 million in 2024 to RMB 5.59 million in 2025, representing a year-on-year growth of over 103%.As algorithms become increasingly open-source and computing power tends toward standardization, what truly sets companies apart lies in data — particularly industry data that has undergone sophisticated governance and can effectively empower large models. Backed by a decade of deep industry expertise, Xunce Technology has established a substantial and sustainable competitive barrier in this domain.ConclusionFrom an early-stage private equity tool provider to a cross-industry AI data infrastructure builder, and from a module supplier to a Token-priced core platform, Xunce Technology has remained committed to unlocking data as a scarce, strategic resource that is freely circulable, readily callable and empowered to drive high-quality decision-making.Amid the rapid emergence of new intelligent economic paradigms, the Company stands at the threshold of a fundamental structural revaluation, with the potential to enter the RMB 100-billion market cap camp. It is a competitor to none, but an indispensable partner to all. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 27, 2026 - (ACN Newswire via SeaPRwire.com) - Analogue Holdings Limited (“Analogue” or the “Company”, together with its subsidiaries, the “Group”) (stock code: 1977), a leading provider of electrical and mechanical (“E&M”) engineering solutions, and information and communications technology services for smart cities, today announced its annual results for the year ended 31 December 2025 (“the Year” or “FY2025”) with net profit growth, contracts-in-hand achieving another record high and order intake more than doubled, providing a solid business foundation for the coming three years and beyond.Financial Highlights- Profit attributable to owners of the Company increased 23.5% to HK$167.0 million.- Contracts-in-hand surged 61.8% to HK$17,878.7 million, hitting another record-high, made possible by a 113.7% increase in order intake to HK$12,913.6 million during the Year.- The intake of new maintenance contracts for housing programmes, environmental projects and lifts and escalators increased 51.4% to HK$1,669 million, reinforcing the recurring revenue stream.- The Group maintained a strong cash position, with bank balances and cash of HK$1,020.8 million and gearing ratio reduced to 10.1% for FY2025 from 26.2%.- The Board has resolved to pay a second interim dividend of HK2.9 cents per share. Total dividend for the year amounted to HK5.5 cents per share with 25.6% increment year-on-year.Chairman Dr Mak Kin Wah said, “The Year 2025 saw profound changes around the world, with challenges and yet also opportunities. Our Group has continued to stride forward: upholding what we commit by delivering the fundamentals well, striving for continuous improvement to make transformation actionable, investing in technology advancement and productivity, and bringing Hong Kong’s engineering excellence to the world. We are pleased to report that the Group achieved profit growth, secured a record level of contracts-in-hand, and continued to build on our international market presence. These accomplishments highlight our distinctive comprehensive capability across diverse business segments, our commitment to excellence, and our leadership in advanced engineering techniques.”“Supported by strong cashflow, we are in a strong position to take on additional work where appropriate and to seize high-value opportunities as they arise. We will continue to stay agile and focused on capturing opportunities across our broad portfolio, build on our competitive strengths through continuous improvement, and reinforce the use of innovative solutions that enhance quality, safety and performance. We remain steadfast in our commitment to our customers, recognising that this is fundamental to earning their trust and cultivating enduring, strategic partnerships. Guided by our motto – ‘We Commit. We Perform. We Deliver’ – we will continue to maximise value for customers, shareholders, suppliers and stakeholders, while contributing to the communities we serve.”Business Review: Building Services- This segment remains the largest revenue contributor, with revenue reaching HK$3,279 million.- Contracts-in-hand reached a record-high level of HK$8,297 million with the total value of new contracts secured in FY2025 doubled to HK$6,470 million. The Group’s competitive edge in multidisciplinary packaged projects and its industry leadership in innovative MiMEP and other new engineering techniques helped it to secure major contracts.- With strategic investments to accelerate innovation and modern manufacturing facilities in Zhuhai and Hong Kong, the Group continues to lead in MiMEP and DfMA technologies.- Following the successful acquisition of a property management licence, the Group expanded its business to deliver integrated solutions across the entire building lifecycle. This new capability, spanning construction, maintenance, operations and long-term facility management, creates a potential revenue stream that complements core services.- Through continuous development of innovative technologies and operational optimisation, the segment is positioning itself to maintain the market competitiveness while exploring opportunities in other markets in Southeast Asia.Environmental Engineering- This segment achieved record-high contracts-in-hand and order intake, increasing 86.9% and 253.7% to HK$8,094 million and HK$5,355 million respectively. Segment revenue also increased by 18.0% year-on-year to HK$1,591 million.- The segment maintained active tendering throughout the period and was awarded significant contracts, including contracts of a record-breaking value to relocate sewage treatment works in Sha Tin to caverns, sewage pumping station at Ma On Shan and more.- Formed a joint venture company in Qingyang city to explore the operation and maintenance business in the Chinese Mainland.- Explored project opportunities in Asia and the Middle East and the expansion of its expert services into Europe.Information, Communications and Building Technologies (“ICBT”)- Segment revenue remained at HK$630 million. Contracts-in-hand totalled HK$852 million at the year end, and order intake was HK$523 million during the Year.- This segment continued to reinforce its leadership in green and intelligent building solutions under the DigiFusion brand, to enable the development of smarter, more sustainable urban environments.- Continued to leverage ATAL Tower as a platform for developing innovative technologies and broaden its technological capabilities through strategic collaborations with leading manufacturers in the Chinese Mainland and around the world, to strengthen its ability to deliver scalable, high-performance solutions across a wide range of sectors.Lifts and Escalators- Revenue and order intake increased 11.0% to HK$587 million and by 3.2% to HK$566 million respectively.- Transel Elevator & Electric Inc. (TEI), the associate company in the United States (US), secured a contract for the world-class vertical transportation system in the iconic 56-storey luxury hotel skyscraper on the border of Times Square in New York. TEI also further strengthened its market position by extending its footprint into the Southeastern part of US.- Actively built on its presence in the UK and broadened its network across other international markets, reinforcing its global ambitions in vertical transportation solutions.- Machine-Room-Less lift products continued to gain traction in key international markets- Streamlined the manufacturing processes of Nanjing factory, broadened its product portfolio and strengthened the overall product quality, aligning with the Group’s global vision and reaffirming its commitment to delivering reliable, high-performance vertical transportation solutions.For further details of the 2025 Annual Results, please refer to the announcement filed with The Stock Exchange of Hong Kong Limited.About Analogue Holdings LimitedEstablished in 1977, Analogue Holdings Limited is a leading provider of electrical and mechanical (“E&M”) engineering solutions and information and communications technology (“ICT”) services for smart cities, with headquarters in Hong Kong and operations in the Chinese Mainland, Macau, the United States, the United Kingdom, Germany, Singapore and Malaysia. Serving a wide spectrum of customers from public and private sectors, the Group provides multidisciplinary and comprehensive E&M engineering and technology services in four major segments, including Building Services, Environmental Engineering, Information, Communications and Building Technologies (“ICBT”) and Lifts & Escalators.The Group also manufactures and sells lifts and escalators internationally and has entered into an alliance with Transel Elevator & Electric Inc. (“TEI”), one of the largest independent lifts and escalators companies in New York, the United States. The Group’s associate partner, Nanjing Canatal Data-Centre Environmental Tech Co., Ltd. (603912.SS), specialises in manufacturing of precision air conditioners. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月27日 - (亞太商訊 via SeaPRwire.com) - 領先的機電工程與智慧城市的資訊及通訊科技服務供應商安樂工程集團有限公司（「安樂工程」或「公司」，連同附屬公司統稱「集團」）（股份代號：1977），今天宣佈截至2025年12月31日止年度（「年內」或「2025財政年度」）的全年業績，除淨利潤錄得增長，集團的手頭合約更再創新高，訂單額增長逾倍，為未來三年及往後的發展奠下穩固基礎。財務摘要- 本公司擁有人應佔溢利按年增23.5%至1.670億港元- 手頭合約增61.8%至178.787億港元，再創歷史新高，受惠於年内訂單額增長113.7%至129.136億港元- 新增維修保養合約涵蓋房屋項目、環保項目以及升降機及自動梯，合約額增51.4%至16.69億港元，鞏固經常性收入來源- 集團維持強健現金水平，銀行結餘及現金為10.208億港元，資產負債比率則由26.2%降低至2025財政年度的10.1%- 董事會已決議派付第二次中期股息每股2.9港仙；全年合共派息每股5.5港仙，較上年度増25.6%主席麥建華博士表示：「2025年見證了全球的重大變化，挑戰與機遇並存。集團穩步向前，以謹慎履行承諾作堅實基礎，不斷精益求精，更推動革新落到實處、投資提升技術及生產力，引領香港工程的卓越實力踏上環球市場。我們欣然宣布，集團實現了利潤增長，更創下歷史新高的手頭合約水平，並持續鞏固在國際市場的影響力。這些成就彰顯了我們在各個業務領域的綜合能力，對卓越品質的承諾，以及在先進工程技術方面的領導地位。」「憑著充裕的現金流支持，我們具實力適時開展更多工程項目，並在高價值商機出現時抓緊機會。我們將繼續保持靈活專注，積極把握集團廣泛業務組合中的機遇，透過持續提升我們具競爭力的優勢，並強化應用創新解決方案，以提升工程品質、安全和表現。我們深知為客戶堅定不移地履行承諾，是贏得他們信任及維繫持久夥伴關係的基礎。秉持『重承諾、慎履行、獻成果』的座右銘，我們將繼續為客戶、股東、供應商和其他持份者創造最高利益，同時為我們所服務的社區作出貢獻。」業務回顧：屋宇裝備工程- 此業務板塊繼續成為集團最大的收益來源，收益達32.79億港元。- 手頭合約創下歷史新高，達82.97億港元，於2025財政年度新簽合約增長一倍達64.70億港元。集團在跨多專業的綜合項目中擁有競爭優勢，並有賴在創新的機電裝備合成法和其他新工程技術方面的領導地位成功取得重要合約。- 憑藉策略性投資以加快創新，並在珠海和香港發展現代化製造設施，集團得以在機電裝備合成法和裝配式設計技術方面繼續領先同儕。- 集團通過成功取得物業管理牌照擴大業務以提供可橫跨整個建築週期的綜合解決方案。此涵蓋建造、維修保養、營運，以至長期的設施管理的新能力，開拓了潛在的收益來源，與核心服務互補優勢。- 透過不斷開發創新技術和優化營運，此業務板塊強化自身定位以維持在市場中的競爭優勢，同時探索東南亞其他市場的發展機遇。環境工程- 此業務板塊的手頭合約與新增訂單額創下歷史新高，分別按年增加86.9%及253.7%至80.94億港元及53.55億港元。同時，業務收益按年增加18.0%至15.91億港元。- 此業務板塊於年內維持積極參與投標，並成功贏得標誌性合約，包括合約額破紀錄的搬遷沙田污水處理廠往岩洞、馬鞍山污水泵房等工程項目。- 於慶陽市開立了合營企業，以拓展中國內地的營運及維修業務。- 探索在亞洲和中東地區的項目機遇，並將專業服務拓展至歐洲市場。資訊、通訊及屋宇科技（「ICBT」）- 業務收益維持在6.30億港元，手頭合約價值截至2025年末為8.52億港元，年內新增訂單額為5.23億港元。- 此業務板塊持續以DigiFusion品牌鞏固其在綠色及智慧屋宇解決方案的領導地位，有助打造更智慧化、更可持續的城市環境。- 持續憑藉安樂工程大廈作為平台以研發創新技術，並透過與中國內地及環球領先生產商的策略合作持續擴大技術能力，從而加強在多個範疇的能力以提供可擴大規模的高效解決方案。升降機及自動梯- 收益與新增訂單額分別按年增加11.0%至5.87億港元，以及增加3.2%至5.66億港元。- 集團位於美國的聯營公司Transel Elevator & Electric Inc （「TEI」）取得重大合約，在聳立於紐約時代廣場旁的地標性56層摩天豪華酒店內提供世界級垂直運輸系統。TEI亦將業務版圖拓展至美國東南部，進一步鞏固其市場地位。- 積極加強在英國的業務，並擴大在其他國際市場的網絡，強化在垂直運輸解決方案領域的全球發展的雄心。- 無機房升降機產品繼續在主要國際市場取得進展。- 南京工廠簡化了生產流程，擴大產品種類，並提高了整體產品質量。這些提升正好配合集團的環球視野，肯定其承諾，矢志提供可靠和高效的垂直運輸解決方案。有關2025年度業績詳情，請參閱已呈交香港聯合交易所有限公司的公告。關於安樂工程集團有限公司安樂工程集團有限公司成立於1977年，為領先的機電工程與智慧城市的資訊及通訊科技服務供應商，總部設於香港，業務遍及中國內地、澳門、美國、英國、德國、新加坡及馬來西亞。本集團為公共和私營機構提供跨專業綜合機電及技術服務，涵蓋屋宇裝備工程、環境工程、資訊、通訊及屋宇科技（「ICBT」），以及升降機及自動梯等四大業務板塊。本集團同時製造及向全球銷售升降機及自動梯，並與美國紐約最大獨立升降機及自動梯公司之一 – Transel Elevator & Electric Inc.（「TEI」）達成夥伴關係。本集團的聯營公司南京佳力圖機房環境技術股份有限公司（603912.SS）專門製造精密空調設備。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月27日 - (亞太商訊 via SeaPRwire.com) - 3月26日，海天味業（A股：603288；H股：03288）發佈2025年年度業績報告，面對2025年複雜多變的市場環境，憑藉多元產品矩陣、高效運營體系、硬核科技創新，公司在行業變革浪潮中穩健前行，交出一份彰顯行業龍頭實力與高品質發展成色的優異答卷。財報資料顯示，2025年公司核心經營指標穩健增長，實現營業收入288.73億元，同比增長 7.32%。盈利能力同步提升，全年歸母淨利潤70.38億元，同比增長10.95 %；扣非歸母淨利潤68.45億元，同比增長12.81%；調味品主業毛利率41.78%，同比增加3.15個百分點；各項經營資料均創下歷史新高，盈利品質與增長動力雙雙亮眼，彰顯公司硬核實力。豐富的國民產品矩陣，構築多元增長格局豐富完善的國民級產品矩陣，是海天味業實現穩健增長的核心基石。在產品矩陣方面，海天圍繞用戶需求持續推進品類創新，構建起覆蓋全場景烹飪的一站式產品體系，全方位滿足不同消費群體的多樣化需求。得益于豐富的產品矩陣與優異的產品品質，2025年，公司醬油、蠔油、調味醬等核心品類保持穩健發展，分別實現營業收入149.34億元、48.68億元及29.17億元，同比增長8.55%、5.48%及9.29%，構成業務增長的“金字塔基座”。其中，海天醬油產銷量和市場佔有率已連續數十年位居全國第一，海天蠔油的市場佔有率也連續10年位居全國第一，憑藉優質口感與穩定品質，成為千萬家庭與餐飲機構的首選；公司調味醬已形成產品豐富、風味立體、場景多元的產品體系，涵蓋黃豆醬、香辣醬等具備廣泛消費基礎的大單品，同時亦有柱侯醬、海鮮醬、拌飯醬、香菇醬等適用不同烹飪方式的特色醬料，紫蘇醬、桂林風味辣椒醬等適合不同地域口味的風味醬料，以及蔥油拌麵醬、重慶小面調料等便捷化調味醬，有效滿足用戶需求。此外，為順應消費者對醋類產品的細分化需求，公司堅持「傳統醋+特色醋」的產品佈局，同時不斷推陳出新，推出有機醋、果醋等多元化產品，形成豐富多元的醋類產品體系，進一步彌補品類空白，擴大市場覆蓋面。截至2025年底，公司擁有7個十億級以上產品系列、超30個億級以上產品系列，產品矩陣的豐富度與完整性持續提升。其中，金標生抽、草菇老抽兩大產品系列已暢銷60餘年，味極鮮醬油、海天上等蠔油兩大產品系列連續10餘年實現單品年收入超10億元，成為支撐公司業績穩健增長的「壓艙石」，其市場認可度與用戶忠誠度持續處於行業領先水準。在保持核心品類穩健增長的同時，海天精准把握消費趨勢變化，持續培育新興增長點，不斷豐富產品矩陣的層次與內涵。報告期內，在領先行業的產品力支撐下，以有機和薄鹽為代表的營養健康系列產品實現營業收入同比增速達48.3%，成為拉動業績增長的新引擎；食醋和料酒業務持續發力，規模優勢和體系化能力逐步顯現，市場佔有率穩步提升，為公司長遠發展注入強勁新動能。​值得關注的是，依託供應鏈規模效應、技術研發與柔性生產三大核心壁壘，海天加速從“調味產品供應商”向“一站式風味解決方案提供商”轉型，深度佈局商用市場，實現To C與To B業務雙輪驅動。截至2025年底，公司已為眾多餐飲連鎖、食品工廠及全球頭部零售品牌提供商用調味品一站式解決方案，成為公司業績增長的重要支撐。堅持以用戶為中心，全域深耕驅動效率與價值雙升堅持以用戶為中心，持續優化運營效率與用戶價值，是海天味業保持行業領先地位的關鍵所在。面對消費渠道的多元化變革，海天立足用戶需求，通過數字化賦能傳統渠道、擁抱新興渠道建設、聯動餐飲及工業渠道，實現效率與價值的雙重躍升，進一步鞏固市場滲透率。在傳統渠道方面，海天依託覆蓋全國的終端網路，借助數字化行銷工具和服務模式創新，持續向下沉市場滲透，並延伸到最終用家和消費者，顯著提高了終端覆蓋品質與消費者觸達效率，同時，通過終端管理的精細化升級，讓存量網點煥發新活力。2025年線下渠道營業收入達257.60億元，同比增長7.85%。線上與即時零售等新興陣地，海天主動適應消費場景的變化，通過規範銷售秩序、強化專業運營，實現新興渠道的高品質發展；針對新興渠道的消費特性，公司還推出線上定制化產品，精准匹配消費群體的需求，逐步構建線上與線下協同互促的健康發展模式，2025年線上渠道增幅高達31.87%。在商用渠道方面，依託柔性供應鏈與「銷研產一體化」快速回應機制，海天為餐飲連鎖和食品工廠提供從通用產品到定制化的一站式調味解決方案，實現「3天打樣、15天交付」的高效回應，大幅提升了客戶體驗與合作粘性。目前，餐飲與工業渠道穩健發展，收入占比持續提升，正成長為公司專業增長的重要動力源，進一步拓寬了公司的增長空間。堅持科技立企與創新，驅動價值鏈全面升級堅持科技立企、創新驅動，是海天味業實現高品質發展的核心動力。作為調味品行業數字化轉型的先行者，公司全面擁抱AI時代，推動人工智能、大數據與傳統釀造技藝深度融合，在守護匠心工藝的同時實現提質增效，推動行業從「傳統釀造」向「智慧釀造」轉型升級。海天味業堅持每年將研發投入保持在營業收入約3%的水準，近十年研發投入累計超65億元，累計擁有各類專利超1,000項，形成了完善的研發體系與創新機制。2025年1月，海天高明生產基地獲得全球醬油釀造行業首家「燈塔工廠」認證，標誌著公司數字化轉型已躋身全球行業標杆，也印證了中國調味品企業在智慧製造領域的領先實力。此外，公司部署端到端供應鏈創新用例，將AI與大數據深度應用於研、產、供、銷各環節，實現全鏈條的數字化、智慧化升級。在數字化全面賦能下，海天供應鏈運營效率顯著提升，訂單準時足額交付率（OTIF）不斷提高，綜合成本穩步下降，充分彰顯智慧製造帶來的效率紅利與競爭優勢。受益於在數字化轉型與高品質發展方面的突出成就，海天味業屢獲殊榮。2025年，公司斬獲「CGF中國供應鏈數字化與可持續韌性發展案例」「全國製造業數字化轉型典型案例」等多項殊榮，得到行業與社會的廣泛認可。同時，由海天主導起草的國家標準《食品數字化工廠通用技術要求》正式發佈，填補了國內食品行業數字化工廠通用技術標準的空白，為食品行業數智化升級提供「海天範式」，充分彰顯了公司的行業帶動力與責任擔當。回望2025年，海天味業以穩健業績、多元佈局、硬核實力，在高品質發展之路上行穩致遠，進一步鞏固了行業龍頭地位。展望未來，公司將繼續堅守匠心、深耕主業，持續優化產品矩陣、深化科技賦能、拓展全球市場，以更優質的產品、更高效的服務、更強勁的創新力，守護中國味道、引領行業升級，書寫中國調味品企業全球化高品質發展的嶄新篇章。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月27日 - (亞太商訊 via SeaPRwire.com) - 3月27日，美麗田園醫療健康（02373.HK）正式發佈2025年度業績報告。年內，集團營收、利潤、現金流全方位高質量增長，以硬核業績凸顯行業龍頭的強增長韌性。集團盈利能力實現跨越式躍升。2025年，美麗田園集團總收入30億元，同比增長16.7%；毛利率提升至49.1%，同比提高2.8個百分點；經調淨利潤攀升至3.8億元，同比大幅增長41.0%，經調整淨利率達12.7%，提高2.2個百分點，盈利水平邁上新台階。公司持續顯現「現金牛屬性」。2025年集團經營活動產生的現金流量淨額達10.0億元，同比大幅增長25.4%；截至2025年12月31日，集團現金及類現金項目金額合計高達25.9億元，同比淨增41.6%，充沛且強勁的現金流為集團戰略投資與股東回報提供充足動能。這份營收與利潤大幅增長的亮眼業績，是集團「內生增長+外延並購」商業模式的成功體現，也是集團精益管理、提質增效及數智化賦能帶動整體效率提升的有力印證。「雙美+雙保健」模式賦能，盈利能力全面上揚作為核心基石業務，集團美與健康板塊逆勢高增，全年交出令市場矚目的亮眼答卷。2025年，美容和保健服務收入16.6億元，同比增長14.9%；毛利率提升1.2個百分點至41.9%；直營門店客流達172.4萬人次，同比增長23.2%；直營活躍會員增至14.6萬名，同比增長11.8%，直營活躍會員年均消費金額9738元，同比提升320元。直營活躍會員規模與年均消費實現雙增長。業績高質量增長的同時，集團錨定長期發展戰略。2025年，我們正式發佈超級供應鏈戰略，全面升級產品創研體系。未來，產品創研方式將全新拓展為全球精選、國際品牌合作、國際頂尖實驗室聯合研發三大模式並進，在傳承卓越品質的同時，注入創新動能。2026年2月，我們重磅宣佈與全球知名護膚品牌資生堂達成重磅戰略合作，在品牌影響力、服務體驗、科研共創等多維度深度攜手，開啟美與健康領域合作的新篇章。消費醫療兼具醫療價值屬性與消費彈性，是承載長期結構性機遇的優質賽道。美麗田園集團深耕消費醫療賽道，圍繞高端女性美與健康的核心醫療需求深度延伸佈局。過去16年，我們從0到1自建消費醫療能力，目前全國落地38家消費醫療機構，形成規模化佈局。2025年，消費醫療板塊整體收入13.4億，同比增長18.9%，占收入比例達到44.8%，成為重要的增長驅動力。具體來看，2025年集團醫療美容服務-秀可兒醫美逆勢增長，實現收入10.2億元，同比增長9.6%，毛利率大幅提升3.6個百分點至55.9%；客流10.2萬人次，同比增長13.1%，活躍會員攀升至3.6萬名，同比增長7.7%；活躍會員年均消費27,862元，同比增加490元。為進一步破局行業競爭、打造差異化核心優勢，秀可兒醫美精准錨定「專研抗衰」賽道，以「專家、專研、專注原生美」為品牌定位。2026年3月，Cellcare秀可兒品牌舉辦「專研抗衰」品牌升級發佈會，圍繞不同年齡層女性抗衰需求，打造 「初老抗衰、凍齡抗衰、逆齡抗衰」 的全週期產品藍圖，正式開啟秀可兒專研抗衰新時代。亞健康醫療服務--研源醫療作為集團增值業務迎來爆發式增長。2025年，研源醫療收入3.3億元，同比大增62.2%，收入佔比首次突破10%，成為集團業績增長的重要引擎；毛利率升至64.3%，同比提升6.1個百分點；客流量3.7萬人次，同比增長35.7%，活躍會員人數同比大增37.9%，活躍會員年平均消費28,032元，同比增加6287元。2025年，研源醫療旗下功能醫學板塊收入同比增長101%。在AI浪潮之下，我們將通過自研AI模型，深度融合精准檢測數據、專家診療路徑與臨床案例，實現「千人千面」的個性化診療方案與7x24全天候服務，以科技賦能醫療服務全面升級。研源醫療旗下女性特護板塊收入增長64%。我們將持續拓展服務版圖，構建「預防-治療-抗衰」女性健康醫療服務。並購整合戰略升級，以共贏之姿賦能行業發展中國「美與健康」市場坐擁萬億賽道規模，機遇與挑戰並存，合作共贏已經成為行業發展的必然趨勢。美麗田園主動投身行業整合進程，將投資並購上升為集團級核心戰略，以開放共贏的姿態攜手行業夥伴，共同推動美業高質量發展。2026年3月，集團重磅舉辦「尋找100位美業同行者」戰略投資暨行業賦能發佈會，宣佈將聚焦中國20個高線城市的美與健康服務機構，誠邀更多行業夥伴融入美麗田園生態體系，依託持續打磨精進的商業系統為行業夥伴提供全方位賦能提效，實現共生共贏。這一戰略佈局的底氣，源自集團過往逾30多起收並購項目中所積澱的深厚實戰經驗與可複製的整合方法論。2024年，集團完成對中國美容行業市占率第二大品牌奈瑞兒的收購，並通過系統化、精細化整合，實現奈瑞兒收入和利潤雙提升。2025年，奈瑞兒單店收入從收購前的575萬提升至810萬、經調淨利率從6.5%大幅提升至10.5%，以亮眼的數據印證了美麗田園強大的並購整合能力，更形成了一套可複製、可延展的行業整合成功範式。2025年10月，美麗田園集團宣佈以12.5億元人民幣全資收購行業第三大品牌思妍麗100%股權。伴隨著思妍麗於2026年1月正式併入集團報表，我們將複製奈瑞兒成功經驗，充分發揮自身模式優勢和平台能力，為業績增長注入新動能。至此，三大品牌齊聚美麗田園集團麾下，市場佔有率實現跨越式提升，中國美容行業競爭格局重塑。重磅打造商業系統，構建企業可持續增長核心壁壘33 年深耕，美麗田園集團從美容服務逐步延伸至消費醫療，已成功建成面向高線城市女性的美與健康綜合服務平台。2025年，集團重磅打造美麗田園商業系統，從多維度構建企業可持續增長模式，為長遠發展築牢體系根基。客戶價值成長系統。通過精細化客戶運營體系，我們構建起覆蓋推廣、獲客、轉化、會員留存、價值提升、複購、裂變的全鏈路運營閉環，為客戶持續創造長期價值。強平台+多品牌系統。我們構建了「強平台+多品牌事業部」協同的組織體系，支撐多品牌、多業務高效聯動與協同發展。前台事業部聚焦市場與客戶，靈活作戰、快速響應；平台沉澱能力、輸出標準，讓協同貫穿業務全流程，有效提升運營效率與業務延展性，為多品牌有序擴張提供堅實組織支撐。並購價值成長系統。我們構建了「投資+整合+成長」全週期並購價值成長體系，通過持續積累行業獨特的投資數據、成熟的投前模型、精進的投中整合，全面提升投後價值，形成成熟的並購與賦能機制，可適配不同規模、不同業務的優質標的，真正實現「並購即融合、融合即增值」。數智化與AI系統。集團將構建數智化驅動的管理體系，深度賦能美麗田園商業系統，讓體系能力可落地、可複製、可迭代，成為集團穿越經濟週期、持續引領行業發展的堅實支柱。資本市場價值提升，持續釋放長期投資價值2025年3月，集團正式發佈三大舉措，圍繞股東結構優化、高分紅比例及管理層激勵，持續向資本市場釋放長期投資價值。股東結構優化方面，2025 年 8 月，原PE股東中信產業基金正式退出主要股東行列，同步引入優質長期戰略投資者，股東結構進一步夯實。分紅方面，2026年董事會提議延續高分紅比例，將2025年歸母淨利潤的50%用於分紅，派發每股0.72港元，同比增長38.5%，以真金白銀的回報持續強化股東回報，彰顯企業對自身發展的堅定信心。管理層激勵方面，2025年，集團將未來三年收入及利潤目標與股權激勵深度綁定，首年業績目標已超額達成，激勵機制的有效性得到充分驗證。在此基礎上，公司進一步上調管理層股權激勵對應的三年業績目標，以更高標準統一公司與股東利益，在釋放增長潛力的同時，為投資者創造長期穩定回報。2025 年 11 月，公司成功納入 MSCI 全球小型股指數，進一步進入全球被動及主動型基金視野，吸引更廣泛的國際投資者關注。未來展望：三大超級戰略領航，錨定長期高質量發展美麗田園集團的長期願景是成為中國美與健康的領航者。站在行業整合與品牌升級的新起點，2025年11月，美麗田園正式發佈超級品牌、超級連鎖、超級數字化三大戰略，為未來高質量發展指明方向，擘畫長期發展藍圖。超級品牌，構建美與健康品牌矩陣。我們持續升級專業實力，打造超越客戶期待的體驗，重塑美容行業價值新空間。同時，積極參與並推動行業標準制定，將美麗田園的高標準上升為行業共識，提升消費者信任與品牌價值。超級連鎖，我們將發揮「雙美+雙保健」商業模式優勢，通過內生增長與外延並購雙輪驅動戰略帶動公司價值躍升。我們致力於打造20個收入過億的核心城市，同時構建自有供應鏈能力，融合全球精選與聯合專研，為中國高線城市女性提供兼具專業性、個性化、高品質的美容和消費醫療產品與服務。超級數字化，我們致力於打造數智化與AI系統基礎建設，構建數智化驅動的企業管理體系，打造數智引領的美與健康服務連鎖標杆企業。結語未來，美麗田園將繼續堅守「以客戶為中心」的初心，依託「美麗田園商業系統」，以「三大超級戰略」為指引，在不斷滿足高線城市女性對美與健康的多元需求的同時實現立體增長，推動中國美與健康行業的高質量發展。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

RESULTS HIGHLIGHTS:- The Revenue for the year ended 31 December 2025 was approximately HK$3,736.5 million, representing an increase of approximately 11.1% as compared with the same period last year.- The Gross Profit Margin for the year ended 31 December 2025 was approximately 55.8%; the gross profit was approximately HK$2,085.0 million, representing an increase of approximately 15.9% as compared with the same period last year.- The Group’s EBITDA for the year ended 31 December 2025 was approximately HK$938.1 million, representing an increase of approximately 32.4% as compared with the same period last year.- The Group’s net profit for the year ended 31 December 2025 was approximately HK$601.2 million, representing an increase of approximately 47.7% as compared with the same period last year.- Basic earnings per share for the year ended 31 December 2025 amounted to approximately HK63.7 cents, representing an increase of approximately 47.5% as compared with the same period last year.- The Board recommended the payment of a final dividend of HK15.0 cents per ordinary share for the year ended 31 December 2025.- For the year ended 31 December 2025, the Group recorded approximately 1,039,000 cases digital solution cases produced from the Group’s production facilities in Mainland China, Thailand and Vietnam, reflecting an increase of 32.7% as compared with the same period in 2024 as a result of our clients’ continued adoption of intra-oral scanners.HONG KONG, Mar 27, 2026 - (ACN Newswire via SeaPRwire.com) - 26 March 2026, Modern Dental Group Limited (“Modern Dental” or “the Group”, stock code: 03600.HK), a leading global dental prosthetic device provider, announces its annual results for the year ended 31 December 2025 (“the year”).During the year ended 31 December 2025, the Group’s multi-dimensional strategies and continuous enhancement of operational efficiency and productivity as supported by the ongoing trend of digitalization in the dental industry have resulted in the Group reporting record revenues, net profit and EBITDA numbers during this period. This occurred in a period of challenging macro-economic environment with general softness in demand for dental procedures and trade war uncertainties. The Group has been proactive in its approach to deal with the unprecedented international trade environment leveraging its international production facilities located in Thailand, Vietnam and Mainland China.The global digitalization trend continues to drive consolidation within the dental prosthetics industry, enabling the Group to further expand its market share. Our ongoing digital transformation initiatives are enhancing both customer and patient experiences while improving operational efficiency, further differentiating the Group from competitors and positioning us to outperform industry peers. The Group’s underlying fundamentals remain solid, and we are well positioned to capitalize on emerging opportunities going forward.European BusinessesDuring the year ended 31 December 2025, the European market recorded a revenue of approximately HK$1,887.0 million, representing an increase of approximately HK$268.0 million as compared with the year ended 31 December 2024. This geographic market accounted for 50.5% of the Group’s total revenue. The increase of revenue from the European market was mainly attributable to the increase in sales order volume driven by the launch of new products, such as digital dentures, and our state-of-the-art digital workflows.The Group has been the frontrunner to provide comprehensive digital solutions offerings, ranging from numerous minimal invasive and aesthetic prosthetic solutions to intra-oral scanners and clear aligners, and is well positioned to capture the opportunities arising from the accelerated digitalization trend of the dental industry. The Group continues to aggressively gain market share from international and domestic competitors through our established dental ecosystem solutions with a focus on education and digitalization, which is available within close proximity to our clients; effectively meeting our clients’ high expectations through our various onshore and offshore resources. The Group is committed and will continue to equip ourselves to provide the state-of-the-art digital solutions offerings to the dental community in the market.North American BusinessesDuring the year ended 31 December 2025, the North American market recorded a revenue of approximately HK$696.4 million, representing a decrease of approximately HK$55.7 million as compared with the year ended 31 December 2024. This geographic market accounted for approximately 18.6% of the Group’s total revenue.A significant portion of our business in the North America region comprises higher-end products manufactured domestically by MicroDental Laboratories, Inc. and its subsidiaries (“MicroDental Group”). While demand for discretionary cosmetic treatments remained soft throughout 2025, our centralized digital workflows and network-wide production oversight enabled us to deliver enhanced service quality and operational efficiencies to our North American customers.Our diversified supply bases in the US, China, Vietnam and Thailand continue to provide greater flexibility to navigate US tariff uncertainties — an advantage that sets us apart from competitors. Although digitalization of imported product lines drove growth in mass market cases, implementation of the US tariff in April 2025 introduced new uncertainties and contributed to a slow growth in sales for our import-focused business unit.Greater China BusinessesFor the year ended 31 December 2025, the Greater China market recorded a revenue of approximately HK$615.4 million, representing a decrease of approximately HK$46.8 million as compared with the year ended 31 December 2024. This geographic market accounted for approximately 16.5% of the Group’s total revenue.The Mainland China market faced headwinds from the volume-based procurement policies and a prolonged period of intense price competition and the situation started to stabilize in the second half of 2025. This also led to aggressive promotions for dental implant treatments by Mainland China dental clinics in Hong Kong (which experienced a notable decrease in patient visits in Hong Kong). The Group’s has deliberately pivoted away from low-margin segments and stay focused on serving mid- and high-value customers, ensuring long-term sustainable profitability of the Group’s business.The Group is optimistic in its mid/long-term outlook for this market in particular where the latest procurement-related government measures are expected to (i) standardize the pricing of dental prosthetics and develop price transparency, which would level the playing field; (ii) allow the Group’s leading brand name and reputation to be a key consideration for its client and customer; and (iii) have the Group benefit from its large production team and its ability to allocate resources efficiently according to the customer or client.Australian BusinessesFor the year ended 31 December 2025, the Australian market recorded a revenue of approximately HK$289.1 million, representing an increase of approximately HK$24.4 million as compared with the year ended 31 December 2024. This geographic market accounted for approximately 7.7% of the Group’s total revenue. The increase in revenue from Australia reflected a strong uptake of new digital products driven by the digitalization trend in dental industry and the revenue contribution from the acquisition of Digital Sleep which is partially offset by the depreciation of AUD against HK$ by 2.4% compared with the year ended 31 December 2024.Through our various brands, which offer onshore-and offshore-made products, at multiple price points ranging from economy and standard to premium/boutique, the Group is able to effectively penetrate the entire Australian market. We have invested in local production capacity to provide faster service to our customers, and to provide choices around where the products are made. The Group is one of the largest players in the Australian market and is a preferred supplier to the major corporate dental groups in the market.Other MarketsOther markets primarily include Thailand, Indian Ocean countries, Malaysia, Taiwan and Singapore. For the year ended 31 December 2025, these markets recorded a revenue of approximately HK$248.9 million, representing an increase of approximately HK$182.4 million as compared with the year ended 31 December 2024. This geographic market accounted for approximately 6.7% of the Group’s total revenue. The increase in revenue from Other markets was primarily driven by the revenue contribution from the newly acquired Hexa Ceram.Future Prospects and StrategiesThe global macroeconomic environment remains uncertain, with geopolitical tensions and potential tariff changes continuing to create headwinds. However, the Group’s geographically diversified production footprint and global distribution network position us strongly to navigate these challenges. Unlike many competitors reliant on single-country manufacturing, our operations across China, Vietnam and Thailand (including the newly acquired Hexa Ceram) provide superior resilience and flexibility. This strategy, combined with our ability to adapt quickly to local market conditions, enables the Group to mitigate risks and capitalize on opportunities across regions.The dental industry has continued to demonstrate remarkable resilience, underpinned by irreversible demographic trends, including aging populations and increasing awareness of oral health, which drive consistent long-term demand. Building on our record 2025 performance, the Group is well placed to sustain momentum and further strengthen its market leadership.Digitalization remains an irreversible industry trend that is accelerating consolidation of the dental prosthetics industry. We are at the forefront of this transformation, with digital solution cases now representing approximately 35–40% of total volume. Our centralized digital workflows, intra-oral scanner partnerships, proprietary solutions and global education centers have enhanced operational efficiency, reduced turnaround times and delivered superior customer experiences. These initiatives create high entry barriers and will continue to drive margin expansion and market share gains in the coming years.Following the successful integration of Hexa Ceram (Thailand’s largest dental laboratory, acquired in January 2025) and Digital Sleep Design (Proprietary nylon oral appliance to treat obstructive sleep apnea), our Southeast Asian presence and specialized capabilities have been significantly strengthened. This expansion, coupled with our diversified supply bases in the US, China, Vietnam, and Thailand, provides enhanced flexibility to address potential trade and geopolitical risks while supporting faster regional delivery.Looking ahead, the Group remains committed to reinforcing its worldwide leading position through a multi-dimensional approach. We will continue to pursue selective acquisitions, joint ventures and partnerships to expand and complement our product offerings, particularly in our high-growth clear aligner, Trioclear, while strengthening our distribution and sales networks. Ongoing investments in mass-scale production facilities, AI, automation, research and development, and digital innovation will drive efficiency gains and secure our position at the forefront of the industry.About Modern Dental GroupModern Dental Group Limited (Stock code: 03600.HK) is a leading global dental prosthetics provider, distributor and consultant with a focus on providing custom-made prostheses to customers in the growing prosthetics industry. Our product portfolio is broadly categorized into three product lines: fixed prosthetic devices, such as crowns and bridges; removable prosthetic devices, such as removable dentures; and other devices, such as orthodontic devices, sports guards, clear aligners, and anti-snoring devices. Modern Dental Group has a global portfolio of respected brands, including Labocast, Permadental and Elysee Dental in Western Europe, YZJ Dental in China, Modern Dental Lab in Hong Kong, Modern Dental USA and MicroDental in the United States, Modern Dental Pacific in Australia and New Zealand, Modern Dental SG in Singapore, Modern Dental TW in Taiwan, Apex Digital Dental in Malaysia and Hexa Ceram in Thailand. We have grown these brands by providing premium and consistent quality products and superior customer service. We have more than 80 service centers in over 28 countries and serve over 35,000 customers. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

業績摘要：- 截至2025年12月31日止年度收益約為37.4億港元, 同比增加約11.1%。- 截至2025年12月31日止年度毛利率約為55.8% ；毛利約為20.8億港元，同比增加約15.9%。- 截至2025年12月31日止EBITDA 約為9.4億港元，同比增加約32.4%。- 本集團於截至2025年12月31日止純利約為6.0億港元，同比增加47.7%。- 截至2025年12月31日止每股基本盈利約為63.7港仙，相較去年同期增加約47.5%。- 董事會建議宣派截至 2025年12月31日止年度末期股息每股普通股15.0港仙。- 截至2025年12月31日止年度，本集團於中國內地、泰國及越南生產設施生產之數碼化解決方案個案增加至約1,039,000件，較2024年同期增加32.7%，原因為更多客戶採用口腔內部掃描器。香港, 2026年3月27日 - (亞太商訊 via SeaPRwire.com) - 2026年3月26日，全球領先之義齒器材供應商 - 現代牙科集團有限公司 (簡稱「現代牙科」或「本集團」，股份代號：03600.HK) 欣然公佈截至2025年12月31日止年度(「年度」) 業績。截至2025年12月31日止年度，在牙科行業數碼化趨勢持續的支持下，本集團的多維度策略及持續提升的營運效率及生產力，使其於本期間的收益、純利及EBITDA數字均創下紀錄新高。雖然期內宏觀經濟環境充滿挑戰，牙科手術的需求普遍疲弱，且貿易戰存在不確定性，然而仍然創下紀錄。本集團利用位於泰國、越南及中國內地的國際生產設施，積極應對前所未有的國際貿易環境。全球數碼化趨勢持續推動義齒行業的整合，使本集團進一步擴大其市場份額。我們持續的數碼轉型措施提升客戶及病人體驗的同時，進一步使本集團在競爭對手中脫穎而出，表現優於同業。本集團的相關基礎仍然穩固，並將全力以赴把握未來機遇。歐洲市場業務截至2025年12月31日止年度，歐洲市場錄得收益約18.9億港元，較去年增加約2.7億港元，此地理市場佔本集團收益總額50.5%。歐洲市場收益增加主要由於新產品的推出(例如數碼化義齒)及我們最先進的數碼化流程，推動銷售訂單量增加。本集團已成為提供全面數碼化解決方案的先驅，範圍涵蓋多項微創及美容義齒解決方案以至口腔內部掃描儀及透明矯正器，本集團已準備好把握牙科行業數碼化趨勢加速帶來的機遇。本集團繼續透過所建立，重點為教育及數碼化且非常鄰近客戶的牙科生態系統解決方案，積極從國際及本地競爭對手取得市場份額；透過不同的境內及境外資源有效地滿足我們客戶的高期望。本集團一直致力並將繼續裝備好自己，為市場上的牙科領域提供最先進的數碼化解決方案。北美市場業務於截至2025年12月31日止年度，北美市場錄得收益約7.0億港元，較去年減少約5,570萬港元，此地理市場佔本集團收益總額約18.6%。我們在北美地區的大部分業務包括MicroDental Laboratories, Inc.及其附屬公司(「MicroDental集團」)在本地製造的高端產品。雖然2025年對主動美容治療的需求仍然疲弱，然而我們的中央化數碼流程及對區內廣泛生產單位的網絡讓我們為北美客戶交出更高服務質素及營運效率。我們位於美國、中國、越南及泰國等地的多元化供應基地，繼續在應對美國關稅的不確定性時帶來更大彈性－此為將我們與競爭對手作區分的優勢。雖然進口產品線的數碼化帶動大型市場個案的增長，然而2025年4月在美國實施的關稅帶來新的不確定性及為我們以進口為主的業務單位的銷售帶來緩慢增長。大中華市場業務截至2025年12月31日止年度，大中華市場錄得收益約6.2億港元，較去年減少約4,685萬港元，此地理市場佔本集團收益總額約16.5%。中國內地市場面對帶量採購政策及價格激烈競爭延長的逆境，而於2025年下半年情況開始穩定。此亦導致中國內地牙科診所積極於香港推廣種植牙治療(香港患者就診人數明顯減少)。本集團有意退出低利潤分部，並專注於中及高價值客戶，確保本集團業務能夠長期及可持續獲利。本集團對此市場的中長期前景感到樂觀，特別是在政府最新的採購相關措施中，預計(i)規範義齒價格及建立價格透明度，平衡中心點；(ii)讓本集團領先的品牌名稱及聲望成為客戶及顧客的主要考量；及(iii)讓本集團從其龐大生產團隊中得益及根據顧客或客戶有效分配資源的能力。澳洲市場業務截至2025年12月31日止年度，澳洲市場錄得收益約2.9億港元，較去年增加約2,438萬港元，此地理市場佔本集團收益總額約7.7%。澳洲的收益錄得增長，反映牙科行業數碼化趨勢帶動大量新的數碼化產品，以及收購Digital Sleep的收益貢獻，但部分被相較於截至2024年12月31日止年度，澳元兌港元貶值2.4%所抵銷。透過我們不同的品牌(可提供境內及境外製造的產品)，憑藉涵蓋從經濟及標準至優質/精品等的多種價位，本集團能夠有效地滲透整個澳洲市場。我們投資於本地產能，以為客戶提供更快捷的服務，並可供選擇產品之生產地。本集團為澳洲市場最大參與者之一並為市場內主要企業牙科團體的首選供應商。其他市場其他市場主要包括泰國、印度洋國家、馬來西亞、台灣及新加坡。截至2025年12月31日止年度，該等市場錄得收益約2.5億港元，較截至2024年12月31日止年度增加約1.8億港元。此地理市場佔本集團收益總額約6.7%。其他市場的收益增加主要由於新收購的Hexa Ceram帶來的收益貢獻所致。未來前景及策略全球宏觀經濟環境仍然不明朗，地緣政治的緊張局勢及關稅的潛在變動繼續營造不利環境。然而，本集團的生產遍及全球各地，而全球分銷網絡讓我們在面對該等挑戰時享有獨特優勢。有別於依賴單一國家生產的一眾競爭對手，我們的營運遍佈中國、越南及泰國(包括新收購的Hexa Ceram)等地，讓我們面對挑戰時能夠進退有據，靈活應變。此策略連同我們快速適應當地市場環境的能力，使本集團降低風險，同時把握各地區的新興機遇。牙科行業繼續展現卓越的適應力，在不可逆轉的人口趨勢下加以突顯，包括人口老化及人們對口腔健康的意識提高，持續帶動義齒的長期需求。本集團建基於2025年創記錄的表現而處於有利位置，能夠保持良好勢頭，同時進一步強化市場的領導地位。行業數碼化勢不可擋，加快義齒行業的整合。我們處於轉型的尖端，目前數碼化解決方案個案佔總銷量約35至40%。我們的中央化數碼工作流程、有關口腔內部掃描儀的夥伴關係、專有的解決方案及全球教育中心有助提升營運效率、縮短處理時間及提供卓越的客戶體驗。有關措施創造高進入門檻，並將於未來數年繼續擴大利潤及增加市場份額。在成功整合於2025年1月收購的泰國最大牙科實驗室Hexa Ceram及Digital Sleep Design(用於治療阻塞性睡眠窒息症的專利尼龍口腔矯正器)後，我們在東南亞地區的影響力及專業能力已經大幅提升。是次擴張連同我們位於美國、中國、越南及泰國等地的多元化供應基地，讓我們在應對潛在的貿易及其他地緣政治風險時帶來更大彈性，同時支持區內快速交付。展望將來，本集團仍然致力透過多角度方針強化其全球領導地位。我們將繼續尋求具針對性的收購、合營企業及夥伴關係，以擴大及補充我們所提供的產品，特別是我們高增長的透明矯正器TrioClear，同時加強我們的分銷及銷售網絡。我們在大型生產設施、AI、自動化、研發及數碼創新方面的持續投資，使效率大幅增高，從而確保我們一直處於行業尖端。關於現代牙科集團現代牙科集團有限公司 (股份代號: 03600.HK) 為全球領先的義齒器材供應商、經銷商和顧問，專注於發展迅速的義齒行業為客戶提供定制式義齒。我們的產品組合大致可分為三類﹕固定義齒器材，例如牙冠及牙橋；活動義齒器材，例如活動義齒；及其他器材，例如正畸類器材、透明牙套、運動防護器及防鼾器。 現代牙科集團擁有多個備受稱許的全球品牌，包括西歐的Labocast、Permadental及Elysee Dental、中國的洋紫荊牙科器材、香港的現代牙科器材、美國的Modern Dental USA及MicroDental、澳洲及新西蘭的Modern Dental Pacific、新加坡的Modern Dental SG、臺灣的 Modern Dental TW、馬來西亞的 Apex Digital Dental及泰國的Hexa Ceram等。我們提供穩定和優質的產品及卓越的客戶服務，令這些公司品牌能茁壯成長。我們於全球超過 28個國家擁有超過 80 家服務中心及服務逾 35,000 名客戶。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HIGHLIGHTS:- Total gross billings amounted to approximately RMB3,955.0 million, representing an increase of approximately 12.8% from approximately RMB3,505.9 million for the corresponding period.- Total revenue was approximately RMB3,430.1 million, representing an increase of approximately 48.7% from approximately RMB2,306.0 million for the corresponding period.- The profit attributable to Shareholders of the Group was approximately RMB921.8 million, representing an increase of approximately 238.5% from approximately RMB272.4 million for the corresponding period.- Non-HKFRS adjusted profit for the year (excluding the share-based compensation expenses) was approximately RMB1,022.5 million, representing an increase of approximately 191.8% from approximately RMB350.5 million for the corresponding period.- Taking into account the financial and cash flow positions of the Group, the Board recommends the payment of a final dividend of approximately HKD168.5 million for the year ended December 31, 2025, representing HKD0.36 per share (in cash), and the proposed final dividend is subject to consideration and approval by Shareholders at the AGM.HONG KONG, Mar 27, 2026 - (ACN Newswire via SeaPRwire.com) - JF SmartInvest Holdings Ltd (the “Company” ; together with its subsidiaries, the "Group" or “we”) is pleased to announce its consolidated annual results for the year ended December 31, 2025 (the “Reporting Period”). During the Reporting Period, leveraging its “technology + investment research” dual-drive strategy, the Group achieved outstanding performance. Supported by robust cash flow and profitability, the Board has proposed a final dividend of HK$0.36 per share, bringing the total dividend for the full year to approximately HK$407.4 million when combined with the interim dividend already paid, reflecting its commitment to delivering returns to shareholders.Strong Financial Performance with Substantial Profitability ImprovementDuring the Reporting Period, the Group continued to advance product innovation, AI applications, and investment research capabilities, driving solid growth across its business. Total revenue for the year reached RMB3,430.1 million, representing a YOY increase of 48.7%. Gross profit amounted to RMB2,821.0 million, up 48.9% YOY, while the gross profit margin remained at a high level of 82.2%, indicating the favourable economies of scale and earnings quality of the Group’s business model.In terms of profitability, profit attributable to equity shareholders surged by 238.5% YOY to RMB921.8 million. Excluding share-based compensation expenses, non-HKFRS adjusted profit for the year reached RMB1,022.5 million, representing a YOY increase of 191.8%, fully demonstrating the effective strategy execution and market adaptability of the Group.The Group places great emphasis on shareholder returns. The Board recommends the payment of a final dividend of approximately HKD168.5 million for the year ended December 31, 2025, representing HKD0.36 per share (in cash). Together with the interim dividend of approximately HK$238.9 million already distributed, the total dividend for 2025 will amount to approximately HK$407.4 million. The steady dividend policy fully reflects the Group’s ample cash reserves and its firm confidence in future development prospects.Continued Optimisation of Product Matrix and Enhancement of Diversified Service SystemDuring the Reporting Period, the Group continued to build a diversified product matrix, enriching its product portfolio in response to different customer needs. VIP products 'Stock Navigator, Super Investor' were steadily optimized, with the addition of several quantitative products and AI-powered products. We also launched a 24/7 AI intelligent customer service system, which significantly improved service efficiency. The live streaming system was upgraded, with sessions increasing by 36% YOY and average daily unique viewers exceeding 100,000.Relying on an integrated “AI + content + service + tools” solution, the Enjoy-Stock Pad recorded net sales volume exceeding 75,000 units during the Reporting Period. The Jiuyao Stocks launched over 80 lightweight products, converting professional investment research capabilities into standardised products. The SmartInvest APP completed its strategic transformation from a tool to a platform, with monthly active users increasing by more than 40% YOY and the 30-day retention rate remaining above 50%.The Group further enhanced its product matrix with two new products, Decision Master and Star-tier Services, filling the gap in the mid-tier product system and enabling a seamless trading service experience. Decision Master focuses on three AI+ investment research modules - themes, value investing and quantification - comprehensively enhances investment decision-making capabilities of individual investors. Star-tier Services collaborates with multiple securities brokerages and partners to create a fully integrated closed-loop ecosystem of“tools-services-trading”, serving over 50,000 users during the Reporting Period.Guided by Technological Innovation, Striving Towards “Investment Advisory Intelligent Agent 2.0”The Group regards innovation and technological R&D as its core driving force, accelerating its transformation towards “digital intelligence”, and advancing towards the era of “investment advisory intelligent agent 2.0”. During the Reporting Period, R&D expenses amounted to approximately RMB356 million, with R&D personnel reaching 624, a YOY increase of approximately 42.8%. The Group held 158 software copyrights and patents in AI, big data and product features, with 22 new items added on a year-on-year basis.The self-developed FinSphere Agent Large Model Assistant V3.0 passed the Large Model Assistant Functionality Completeness Test conducted by the China Academy of Information and Communications Technology, becoming the first large-model application in the securities industry. During the Reporting Period, it served approximately 664,000 customers with cumulative services of 22.58 million. The digital intelligent investment robo-advisor “Jiu Ge” served approximately 600,000 customers with cumulative services exceeding 19 million. The Group also launched stock diagnosis intelligent agent 4.0, AI Xiaoce Q&A assistant, and established an intelligent compliance and risk control platform covering the entire business workflow, indicating that the group's AI capabilities have gradually been implemented in core scenarios.To strengthen its technological foundation, the Group established a technology subsidiary, Jiufang Zhiqing, and set its foothold in “Shanghai Foundation Model Innovation Center”, China’s first large model innovation ecosystem community. The subsidiary serves as the Group’s core AI vehicle for operating a native service technology system, promoting the deep application of AI in scenarios such as investment research, investor education, and risk control.Deep-Rooted Investment Research as the Cornerstone, Adhering to Buyer-Side Advisory and Deepening the “1+N” Investment Research SystemThe Group continues to deepen its “1 research institute and N business lines” investment research system, with the JF Financial Research Institute as investment research hub. The Institute has established a pyramidal-structured professional talent echelon led by Chief Economist Dr. Xiao Lisheng, comprising 4 experts, 8 super-IPs and 128 professionals. As of the end of the Reporting Period, the Group had 576 employees holding securities investment advisory qualifications and 2,628 employees holding securities practitioners, maintains a leading team scale and structure in the industry.During the Reporting Period, The Institute conducted more than 300 research activities, covering more than 2,000 listed companies. The Institute authored approximately 1,200 in-depth research reports and 45 sets of thematic courses with a total duration of 2,000 minutes, continuously enhancing the professional capabilities of buyer-side consultants.Multi-Dimensional, Full-Funnel Traffic Operation to Unlock New Growth DimensionsDriven by AI technology, the Group positions refined MCN-based traffic operations as a central hub connecting users with its business, building an integrated, synergistic omni-channel traffic ecosystem comprising “public-domain MCN (multi-platform) + private-domain + proprietary APP”. On the technological front, the Group applied AIGC to restructure content production, shifting from manual creation to “human-machine collaboration” model, and established a data flywheel integrating “advertising data, model training and operational automation”. During the Reporting Period, the Group consolidated its leading position on online short-video and live streaming platforms’ operations, established a multi-platform coordinated traffic matrix, and developed a multi-tiered, high-quality content ecosystem. It also pioneered e-commerce models for the Enjoy-Stock Pad and AppStore models for the APP, driving deep integration between traffic operations and product features.Future OutlookMr. Chen Wenbin, chairman of the Board and chief executive officer of JF SmartInvest Holdings Ltd, said: “In 2025, we remained committed to the dual-drive strategy of ‘technology + investment research’. Not only did we achieve leapfrog growth in performance, but we also successfully led the industry into the era of ‘Investment Advisor Agent 2.0’. Leveraging artificial intelligence and big data technologies, we developed AI products such as the JF Robo-Advisor, FinSphere Agent and FinSphere Report, achieving industry-leading innovations and scenario-based applications, helping users accomplish the critical transition from ‘cognitive improvement’ to ‘decision optimisation’. At the same time, we transformed our professional investment research capabilities into easily accessible lightweight services, realising a strategic shift ‘from tool to platform’. We uphold the principles of rational investing, value investing and long-term investing, assisting clients in developing sound investment philosophies.“In the future, the Group will focus on four key strategic dimensions. First, deepening AI-driven empowerment across all scenarios, accelerating the iteration of AI agents and their commercialisation on the consumer side, and driving the Group’s digital and intelligent transformation. Second, leveraging Forthright Securities and Forthright Capital’s licenses, advancing the globalisation strategy by exporting the Jiufang’s core models, accelerating overseas business expansion. Meanwhile, promoting license upgrading and strategic investment layout to further improve the construction of digital asset infrastructure. Third, strengthening product-driven business diversification and synergies, deepening cooperation with licensed financial institutions such as securities brokerages, and building a service closed loop covering pre-investment, in-investment and post-investment. Fourth, continuing to optimize the customer operation system, unlocking the value of traffic through full-funnel traffic initiatives, and achieving long-term customer retention. We are dedicated to making investing simpler and more professional while enhancing investors’ sense of fulfillment in investment and wealth management.”About JF SmartInvest Holdings Ltd (Stock Code: 9636)JF SmartInvest Holdings Ltd is a new generation stock investment assistant. The Company is engaged in the provision of equity investment instruments, securities investment advisory, investor education and other services to individual investors. The products include stock quote software, the AI Stock Machine, Stock Navigator, Super Investor and Jiuyao Stocks. The Company adopts the technology + investment research model, develops JF Robo-Advisor, FinSphere Agent, FinSphere Report and other products based on artificial intelligence (AI) and big data technology, which are applied to the industry in terms of innovative practice and scenario application.For enquiries, please contact:Financial PR (HK) LimitedEmail: ir@financialpr.hkTel: 852 2610 0846Fax: 852 2610 0842 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com